vs
MESA LABORATORIES INC（MLAB）とUNITED STATES LIME & MINERALS INC（USLM）の財務データ比較。上の社名をクリックして会社を切り替えられます
UNITED STATES LIME & MINERALS INCの直近四半期売上が大きい（$87.9M vs $65.1M、MESA LABORATORIES INCの約1.4倍）。UNITED STATES LIME & MINERALS INCの純利益率が高く（34.7% vs 5.6%、差は29.2%）。UNITED STATES LIME & MINERALS INCの前年同期比売上増加率が高い（9.8% vs 3.6%）。UNITED STATES LIME & MINERALS INCの直近四半期フリーキャッシュフローが多い（$25.7M vs $18.0M）。過去8四半期でUNITED STATES LIME & MINERALS INCの売上複合成長率が高い（10.8% vs 5.1%）
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
米国石灰鉱物株式会社は米国を本拠地とする天然資源企業で、高カルシウム石灰、ドロマイト石灰、石灰岩および関連鉱物製品を製造・販売しています。主な顧客層はインフラ建設、鉄鋼製造、農業土壌改良、環境排出抑制、産業加工の各分野にわたり、北米全域に顧客を抱えています。
MLAB vs USLM — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $87.9M |
| 純利益 | $3.6M | $30.5M |
| 粗利率 | 64.2% | 48.0% |
| 営業利益率 | 12.2% | 41.0% |
| 純利益率 | 5.6% | 34.7% |
| 売上前年比 | 3.6% | 9.8% |
| 純利益前年比 | 316.6% | 13.2% |
| EPS（希薄化後） | $0.65 | $1.06 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $65.1M | $87.9M | ||
| Q3 25 | $60.7M | $102.0M | ||
| Q2 25 | $59.5M | $91.5M | ||
| Q1 25 | $62.1M | $91.3M | ||
| Q4 24 | $62.8M | $80.1M | ||
| Q3 24 | $57.8M | $89.4M | ||
| Q2 24 | $58.2M | $76.5M | ||
| Q1 24 | $58.9M | $71.7M |
| Q4 25 | $3.6M | $30.5M | ||
| Q3 25 | $2.5M | $38.8M | ||
| Q2 25 | $4.7M | $30.8M | ||
| Q1 25 | $-7.1M | $34.1M | ||
| Q4 24 | $-1.7M | $27.0M | ||
| Q3 24 | $3.4M | $33.4M | ||
| Q2 24 | $3.4M | $26.1M | ||
| Q1 24 | $-254.6M | $22.4M |
| Q4 25 | 64.2% | 48.0% | ||
| Q3 25 | 61.5% | 51.2% | ||
| Q2 25 | 62.0% | 45.8% | ||
| Q1 25 | 61.8% | 50.6% | ||
| Q4 24 | 63.3% | 44.3% | ||
| Q3 24 | 61.3% | 48.2% | ||
| Q2 24 | 64.0% | 45.5% | ||
| Q1 24 | 62.1% | 42.7% |
| Q4 25 | 12.2% | 41.0% | ||
| Q3 25 | 7.8% | 45.3% | ||
| Q2 25 | 5.1% | 39.0% | ||
| Q1 25 | 2.4% | 43.7% | ||
| Q4 24 | 9.2% | 38.8% | ||
| Q3 24 | 6.1% | 42.6% | ||
| Q2 24 | 9.6% | 39.1% | ||
| Q1 24 | -460.6% | 35.9% |
| Q4 25 | 5.6% | 34.7% | ||
| Q3 25 | 4.1% | 38.0% | ||
| Q2 25 | 8.0% | 33.7% | ||
| Q1 25 | -11.4% | 37.4% | ||
| Q4 24 | -2.7% | 33.7% | ||
| Q3 24 | 5.9% | 37.3% | ||
| Q2 24 | 5.8% | 34.0% | ||
| Q1 24 | -432.2% | 31.3% |
| Q4 25 | $0.65 | $1.06 | ||
| Q3 25 | $0.45 | $1.35 | ||
| Q2 25 | $0.85 | $1.07 | ||
| Q1 25 | $-1.30 | $1.19 | ||
| Q4 24 | $-0.31 | $-2.20 | ||
| Q3 24 | $0.63 | $1.16 | ||
| Q2 24 | $0.62 | $0.91 | ||
| Q1 24 | $-47.26 | $3.92 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $29.0M | $371.1M |
| 総負債低いほど良い | $68.4M | $0 |
| 株主資本純資産 | $186.7M | $630.8M |
| 総資産 | $434.8M | $681.0M |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | 0.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $29.0M | $371.1M | ||
| Q3 25 | $20.4M | $349.5M | ||
| Q2 25 | $21.3M | $319.9M | ||
| Q1 25 | $27.3M | $300.6M | ||
| Q4 24 | $27.3M | $278.0M | ||
| Q3 24 | $24.3M | $255.0M | ||
| Q2 24 | $28.5M | $222.5M | ||
| Q1 24 | $28.2M | $207.0M |
| Q4 25 | $68.4M | $0 | ||
| Q3 25 | $69.4M | $0 | ||
| Q2 25 | $70.3M | $0 | ||
| Q1 25 | $71.3M | $0 | ||
| Q4 24 | $72.2M | $0 | ||
| Q3 24 | $73.1M | $0 | ||
| Q2 24 | $74.1M | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $186.7M | $630.8M | ||
| Q3 25 | $178.5M | $602.3M | ||
| Q2 25 | $172.5M | $563.3M | ||
| Q1 25 | $159.8M | $532.2M | ||
| Q4 24 | $155.2M | $497.7M | ||
| Q3 24 | $161.5M | $474.2M | ||
| Q2 24 | $150.7M | $441.1M | ||
| Q1 24 | $145.4M | $415.3M |
| Q4 25 | $434.8M | $681.0M | ||
| Q3 25 | $430.4M | $652.8M | ||
| Q2 25 | $435.7M | $607.4M | ||
| Q1 25 | $433.3M | $585.3M | ||
| Q4 24 | $433.3M | $543.2M | ||
| Q3 24 | $454.1M | $521.8M | ||
| Q2 24 | $440.4M | $484.2M | ||
| Q1 24 | $446.8M | $464.0M |
| Q4 25 | 0.37× | 0.00× | ||
| Q3 25 | 0.39× | 0.00× | ||
| Q2 25 | 0.41× | 0.00× | ||
| Q1 25 | 0.45× | 0.00× | ||
| Q4 24 | 0.47× | 0.00× | ||
| Q3 24 | 0.45× | 0.00× | ||
| Q2 24 | 0.49× | 0.00× | ||
| Q1 24 | — | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $18.8M | $45.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.0M | $25.7M |
| FCFマージンFCF / 売上 | 27.7% | 29.2% |
| 設備投資強度設備投資 / 売上 | 1.1% | 22.6% |
| キャッシュ転換率営業CF / 純利益 | 5.17× | 1.49× |
| 直近12ヶ月FCF直近4四半期 | $37.9M | $102.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $18.8M | $45.6M | ||
| Q3 25 | $8.2M | $45.9M | ||
| Q2 25 | $1.9M | $34.0M | ||
| Q1 25 | $12.7M | $39.4M | ||
| Q4 24 | $18.1M | $38.6M | ||
| Q3 24 | $5.3M | $39.0M | ||
| Q2 24 | $10.7M | $21.2M | ||
| Q1 24 | $12.9M | $27.2M |
| Q4 25 | $18.0M | $25.7M | ||
| Q3 25 | $7.1M | $31.3M | ||
| Q2 25 | $884.0K | $20.8M | ||
| Q1 25 | $11.9M | $24.6M | ||
| Q4 24 | $17.3M | $27.6M | ||
| Q3 24 | $3.5M | $33.9M | ||
| Q2 24 | $9.9M | $16.8M | ||
| Q1 24 | $12.3M | $20.3M |
| Q4 25 | 27.7% | 29.2% | ||
| Q3 25 | 11.7% | 30.7% | ||
| Q2 25 | 1.5% | 22.7% | ||
| Q1 25 | 19.2% | 26.9% | ||
| Q4 24 | 27.6% | 34.4% | ||
| Q3 24 | 6.0% | 37.9% | ||
| Q2 24 | 16.9% | 21.9% | ||
| Q1 24 | 21.0% | 28.4% |
| Q4 25 | 1.1% | 22.6% | ||
| Q3 25 | 1.8% | 14.4% | ||
| Q2 25 | 1.7% | 14.5% | ||
| Q1 25 | 1.2% | 16.3% | ||
| Q4 24 | 1.3% | 13.8% | ||
| Q3 24 | 3.1% | 5.8% | ||
| Q2 24 | 1.5% | 5.7% | ||
| Q1 24 | 0.9% | 9.5% |
| Q4 25 | 5.17× | 1.49× | ||
| Q3 25 | 3.32× | 1.18× | ||
| Q2 25 | 0.40× | 1.10× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.43× | ||
| Q3 24 | 1.54× | 1.17× | ||
| Q2 24 | 3.17× | 0.81× | ||
| Q1 24 | — | 1.21× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
USLM
セグメントデータなし
